Selective leukocyte apheresis for the treatment of inflammatory bowel disease.

@article{Abreu2007SelectiveLA,
  title={Selective leukocyte apheresis for the treatment of inflammatory bowel disease.},
  author={M. Abreu and S. Plevy and B. Sands and R. Weinstein},
  journal={Journal of clinical gastroenterology},
  year={2007},
  volume={41 10},
  pages={
          874-88
        }
}
The etiology of inflammatory bowel disease (IBD) is not completely understood, thus current therapies have been empirical and directed at treating symptoms rather than addressing the cause. In IBD, the overexpression of proinflammatory cytokines, such as tumor necrosis factor-alpha, interleukin-1beta, interleukin-6, leads to a persistent intestinal inflammatory response that damages the intestinal mucosa. Recent advances in pharmacologic therapies that target specific cytokines, chemokines, and… Expand
The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review
TLDR
The mode of actions of Adacolumn GMA appears to be more than adsorption of excess neutrophils and TNF‐producing CD14+CD16+ monocytes per se, and the impact of GMA on the immune system is potentially very interesting in the context of treating immune‐related diseases. Expand
Treating inflammatory bowel disease by adsorptive leucocytapheresis: a desire to treat without drugs.
TLDR
By introducing GMA at an early stage following the onset of IBD or before patients develop extensive mucosal damage and become refractory to medications, many patients should respond to GMA and avoid pharmacologics, which should fulfill the desire to treat without drugs. Expand
Treatment options for children and adolescents with inflammatory bowel disease: is granulomonocytapheresis an effective alternative to drug therapy?
TLDR
The argument that GMA is a relevant and effective non-pharmacologic intervention in pediatric IBD setting is reviewed and it is suggested that patients who respond to GMA may attain a favorable long-term clinical course by avoiding pharmacologicals during an early phase of their active IBD. Expand
Juntendo Medical Journal
In recent years, landmark progress has been made in the treatment of patients with inflammatory bowel diseases (IBD). The anti-tumour necrosis factor (TNF)-α antibody era has shown that mucosalExpand
Efficacy of long-interval cytapheresis on steroid-dependent refractory ulcerative colitis.
TLDR
The report shows that LICAP has a therapeutic effect on the reduction and discontinuation of steroid hormone in steroid-dependent refractory UC patients and was effective even in patients who had an unsuccessful history of receiving tapering dosage of steroid hormones by routine CAP. Expand
Investigating the role of proinflammatory CD16+ monocytes in the pathogenesis of inflammatory bowel disease
TLDR
The data suggest that lamina propria, but not peripheral blood, CD16+ monocytes are a crucial proinflammatory cell population in IBD, and a potential target for anti‐inflammatory therapy. Expand
A case of ulcerative colitis complicating anti‐tumor necrosis factor treatment for rheumatoid arthritis: successful treatment with leukocytapheresis
TLDR
The patient had active arthritis in the elbows, knees and shoulders, and the course of her illness indicated that UC had developed in association with the anti-TNF therapy that had been administered for RA treatment, and therefore, theAnti-tumor necrosis factor therapy was discontinued. Expand
Clinical Effectiveness of Selective Granulocyte, Monocyte Adsorptive Apheresis with the Adacolumn® Device in Ulcerative Colitis
TLDR
Homogeneous evidence from seven RCTs shows that GMA apheresis induces a clinical remission in a higher proportion of UC patients as compared to conventional medical therapy. Expand
INTERVENTIONAL STUDIES ON IMMUNOLOGICAL BALANCE IN IBD AND ALLERGIC ASTHMA
TLDR
It is suggested that differences in response to allergen can depend on different capacity to maintain and restore the immunological balance in bronchial mucosa, the Th-balance. Expand
Granulocytapheresis in the treatment of patients with active ulcerative colitis
  • G. Bresci
  • Medicine
  • Expert review of gastroenterology & hepatology
  • 2008
TLDR
Clinical applications and issues concerning the use of granulocytapheresis in ulcerative colitis are reviewed. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 99 REFERENCES
Developments in the apheresis procedure for the treatment of inflammatory bowel disease
  • A. Pineda
  • Medicine
  • Inflammatory bowel diseases
  • 2006
TLDR
Leukocytapheresis has been shown to exert an overall anti‐inflammatory effect, as peripheral leukocytes demonstrated a diminished capacity to produce inflammatory cytokines such as tumor necrosis factor‐&agr;, interleukin (IL)‐1,IL‐6, IL‐8, and IL‐1&bgr;. Expand
Leukocytapheresis as an Adjunct to Conventional Medication for Inflammatory Bowel Disease
  • K. Sawada
  • Medicine
  • Diseases of the colon and rectum
  • 2003
TLDR
Clinical data suggest that leukocytapheresis might be an effective adjunct to therapy for inflammatory bowel disease to promote remission, taper conventional drug dosage, and potentially reduce the number of patients who require colectomy. Expand
Adacolumn for selective leukocytapheresis as a non‐pharmacological treatment for patients with disorders of the immune system: An adjunct or an alternative to drug therapy?
TLDR
Selective depletion of myeloid cells appears to induce anti‐inflammatory effects and represents a non‐pharmacological treatment for patients with active IBD and the treatment has a clear drug‐sparing role. Expand
Preliminary data on the use of apheresis in inflammatory bowel disease
TLDR
Pilot studies with Adacolumn, a selective therapeutic granulocyte/monocyte apheresis device, in patients with IBD have recently been completed in the United States with favorable results. Expand
Immunomodulatory Effects of Granulocyte and Monocyte Adsorption Apheresis as a Treatment for Patients with Ulcerative Colitis
TLDR
In peripheral blood treated with the G-1 beads or peripheral blood from patients with active ulcerative colitis following granulocyte and monocyte adsorption apheresis, a significant suppression of proinflammatory cytokines and the number of CD10-negative premature granulocytes increased, indicating increased turnover of these cells in the circulation. Expand
Adsorptive granulocyte and monocyte apheresis for refractory Crohn’s disease: an open multicenter prospective study
TLDR
GCAP could be effective for inducing remission and improving quality of life in patients with active Crohn’s disease that is refractory to conventional therapy. Expand
Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: A multicenter study
TLDR
Based on the results, it is believed that in patients with active severe UC, patients who are refractory to conventional drugs, granulocyte and monocyte adsorption apheresis is a useful adjunct to conventional therapy. Expand
Leukocytapheresis Is Effective in Inducing But Not in Maintaining Remission in Ulcerative Colitis
TLDR
Leukocytapheresis is an effective treatment of acute corticosteroid-resistant UC but does not prevent the recurrence of UC. Expand
Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study.
  • H. Hanai, F. Watanabe, +11 authors I. Bjarnason
  • Medicine
  • Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • 2003
TLDR
Reduction of circulating granulocyte and monocyte adsorptive apheresis results in alleviation of inflammation and promotes clinical remission in patients with severe active UC that has not responded to intensive corticosteroid treatment. Expand
Clinical evaluation of granulocyte/monocyte apheresis therapy for active ulcerative colitis.
  • K. Kanke, M. Nakano, H. Hiraishi, A. Terano
  • Medicine
  • Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • 2004
TLDR
Granulocytapheresis is an effective adjunct to conventional medication for promoting remission and sparing steroids in patients with active ulcerative colitis and was most effective in steroid-dependent patients. Expand
...
1
2
3
4
5
...